Online bond platforms may offer overseas-regulated products and tax-specific bonds subject to disclosures, compliance safeguards and revised complianc...
Corporate guarantee valuation permits actual ascertainable commission while barring retroactive application and extended-period penalties for bona fid...
Proper-officer jurisdiction under UPGST penalty provisions upheld; participation on merits prevents bypassing the statutory appellate remedy through w...
Transitioned CENVAT credit may validly satisfy mandatory pre-deposit requirements for legacy service tax appeals through Electronic Credit Ledger debi...
Building-plan sanction charges require statutory authority; unauthorised fees and GST were quashed, while labour cess must follow prescribed collectio...
Pure-agent exclusion fails where hotel booking facilitators receive third-party services themselves, making entire customer consideration taxable as r...
Bulk drugs and active pharmaceutical ingredients (APIs) may qualify as "All Drugs and medicines" for concessional IGST treatment where their character, intended use and statutory compliance bring them within the inclusive definition of "drug" under the Drugs and Cosmetics Act. Classification under Customs Tariff Chapters 28 or 29 does not preclude coverage by the description-based drugs and medicines entry, which prevails over general entries for inorganic and organic chemicals. Imports for testing, clinical research, bioavailability or bioequivalence studies retain their pharmaceutical character. The concessional rate applies only if the particular bulk drug or API is not within the specified nil-rate exclusion.
Bulk drugs and active pharmaceutical ingredients (APIs) may qualify as "All Drugs and medicines" for concessional IGST treatment where their character, intended use and statutory compliance bring them within the inclusive definition of "drug" under the Drugs and Cosmetics Act. Classification under Customs Tariff Chapters 28 or 29 does not preclude coverage by the description-based drugs and medicines entry, which prevails over general entries for inorganic and organic chemicals. Imports for testing, clinical research, bioavailability or bioequivalence studies retain their pharmaceutical character. The concessional rate applies only if the particular bulk drug or API is not within the specified nil-rate exclusion.
Note: It is a system-generated summary and is for quick reference only.